All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
A fusion inhibitor for HIV patients being developed by Trimeris Inc. and Hoffmann-La Roche Inc. produced better than expected results in a Phase III trial. (BioWorld Today)
